Protalix BioTherapeutics (PLX) Capital Expenditures Growth (5y) (2015 - 2026)
Protalix BioTherapeutics (PLX) Capital Expenditures Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Protalix BioTherapeutics | 190.95 Mn | 180.16 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.54% |
| Dec 31, 2025 | -68.90% |
| Sep 30, 2025 | 53.07% |
| Jun 30, 2025 | -17.41% |
| Mar 31, 2025 | 45.27% |
| Dec 31, 2024 | 23.29% |
| Sep 30, 2024 | 13.43% |
| Jun 30, 2024 | -21.75% |
| Mar 31, 2024 | -3.00% |
| Dec 31, 2023 | -28.59% |
| Sep 30, 2023 | 33.86% |
| Jun 30, 2023 | -2.77% |
| Mar 31, 2023 | 5.54% |
| Dec 31, 2022 | -17.23% |
| Sep 30, 2022 | -2.12% |
| Jun 30, 2022 | -46.62% |
| Mar 31, 2022 | -21.16% |
| Dec 31, 2021 | -57.97% |
| Sep 30, 2021 | 16.99% |
| Jun 30, 2021 | -2.81% |